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Insulin sensitivityThe role of serine/threonine protein phosphatase 5 (PP5) in the development of obesity and insulin
resistance associated with high-fat diet-feeding (HFD) was examined using PP5-deﬁcient mice
(Ppp5c/). Despite similar caloric intake, Ppp5c/ mice on HFD gained markedly less weight and
did not accumulate visceral fat compared to wild-type littermates (Ppp5c+/+). On a control diet,
Ppp5c/ mice had markedly improved glucose control compared to Ppp5c+/+ mice, an effect dimin-
ished by HFD. However, even after 10 weeks of HFD glucose control in Ppp5c/ mice was similar to
that observed in Ppp5c+/+ mice on the control diet. Thus, PP5 deﬁciency confers protection against
HFD-induced weight gain in mice.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
In modern societies, many humans have adopted a life style
that is sedentary and combined with excessive caloric intake. This
life style can shift normal metabolism in favor of pathways that
promote the storage of energy as fat. The resulting obesity has be-
come an important health problem [1], because excess adiposity
greatly increases the risk of developing a variety of pathological
conditions, including insulin resistance [2], dyslipidemia, type 2
diabetes mellitus (T2DM) [3] and cardiovascular disease [4].
In conjunction with an expansion of adipose tissue mass, there
is often a development of chronic low-grade inﬂammation, recog-
nized by elevated levels of proinﬂammatory cytokines released
from macrophages that invade adipose tissue [5]. Release of these
so-called adipokines, when combined with an excessive amount of
fatty acids, further contributes to the development of insulin resis-
tance and impaired glucose metabolism in muscle, liver, adipose
tissue and pancreatic b-cells [6]. As insulin resistance worsens, ele-
vated levels of glucose and fatty acids combine to produce a so-
called glucolipotoxic effect, in which reactive oxygen species(ROS) are produced at increased levels [7–9]. High levels of ROS
cause oxidative damage, and as pancreatic b-cells express low lev-
els of ROS-scavenging enzymes [10,11], these cells are particularly
susceptible to ROS. Notably, when present at high levels, ROS can
initiate apoptosis in isolated human pancreatic islets [12].
PP5 (PPP5C, Ppp5c) is a PPP-family serine/threonine protein
phosphatase that may act as a double-edge sword in the develop-
ment of T2DM. PP5 is known to interact with several stress pro-
teins, including apoptosis signal-regulating kinase 1 (ASK1), heat
shock protein-90 (HSP-90), and HSP-90 chaperone complex pro-
teins (glucocorticoid receptor [GR], STIP1, CDC37) [13–15]. The
expression and activation of PP5 is responsive to ROS [16]. Follow-
ing ROS exposure PP5 acts to suppress ASK1 signaling; thus, slow-
ing the activation of JNK and progression into apoptosis [13,16]. In
both insulin-secreting MIN6 cells and pancreatic islets isolated
from mice, the loss of PP5 is associated with increased JNK phos-
phorylation and apoptosis following treatment with saturated
fatty acids and H2O2 [17]. These studies indicate that PP5 protects
pancreatic b-cells from ROS-induced apoptosis, suggesting that PP5
may help guard against the development of T2DM. Nonetheless,
PP5 is also known to interact with HSP-90/GR complexes. In GR-
signaling, the suppression of PP5 with siRNA or antisense oligonu-
cleotides is associated with enhanced dexamethasone-induced
gene expression [18] increased accumulation of nuclear GRs [19],
and altered patterns of GR phosphorylation [20,21]. Glucocorti-
coids produce an immunosuppressive response that may be
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However, glucocorticoids also produce a ‘‘pro-diabetic’’ effect, act-
ing to enhance glucose production in the liver, impair insulin-
dependent glucose uptake in peripheral tissues, and inhibit insulin
secretion from pancreatic b-cells [22]. Therefore, it is not yet clear
if the actions of PP5 during the development of insulin resistance
and T2DM in animals will be harmful or beneﬁcial.
The high conservation of PP5 among species (at the level of ami-
no acids, mouse, rabbit, bovine and human PP5 protein share 98%
identity) suggests that the actions of PP5 are conserved in mam-
mals. To help better understand the roles of PP5 in biology, we
generated congenic strains of mice in which exon 1 of the PPP5C
gene was removed genetically (PP5 knockout mice, Ppp5c/) in
the C57Bl/6J background [23]. Studies conducted with embryonic
ﬁbroblasts and pancreatic islets isolated from the Ppp5c/ mice
conﬁrmed the role of PP5 in the suppression of signaling cascades
induced by several forms of genomic stress, including ROS- and
fatty acid-induced apoptosis [17,23]. However, when compared
to their wild-type littermates, the mice lacking PP5 weighed less,
and no loss of b-cell mass was observed in the Ppp5c/ mice.
Further analysis revealed that Ppp5c/mice had lower fasting gly-
cemia and eliminated glucose faster during an glucose tolerance
test, but they retained normal insulin sensitivity and normal fast-
ing insulin levels [17]. Working with cells derived from an inde-
pendently generated line of PP5 knockout mice, Hinds et al.
reported that in adipogenically differentiated mouse embryonic
ﬁbroblasts (MEFs) PP5 may act as a permissive enzyme for adipo-
genesis, by simultaneously suppressing the phosphorylation of GR-
a and peroxisome proliferator activated receptor c (PPARc) at sites
which facilitate lipolysis or lipogenesis, respectively [24]. Here, we
report on a high-fat diet-feeding study which revealed that even on
a diet in which 60% of the calories are derived from fat, a genetic
deletion of PP5 prevents weight gain in mice. These observations
suggest that inhibitors of PP5 may indeed be useful to combat
the development of obesity, and in doing so, prevent obesity-in-
duced insulin resistance.
2. Methods
2.1. Animals and treatment
The experiments were performed on male PP5 knockout ani-
mals (Ppp5c/) that were developed previously [23], using wild-
type (Ppp5c+/+) littermates as controls. Mice of both genotypes
(8 weeks of age) were placed on either a high-fat diet (HFD: 20%
protein, 20% carbohydrates, 60% fat), or on a control diet (CD:
20% protein, 70% carbohydrates, 10% fat) for ten weeks. Body
weight and the intake of water and food were monitored weekly.
Fasting blood glucose (FBG) was measured before the study and
then after ﬁve and nine weeks on the indicated diets. At the same
time points, blood samples were collected. The penultimate week,
mice were allocated to either an intraperitoneal (i.p.) glucose- or
insulin tolerance test (IPGTT, IPInsTT) to evaluate glucose tolerance
and insulin sensitivity, respectively, as previous described [17].
Brieﬂy, prior to the IPGTT mice were fasted 4 h before they re-
ceived i.p. injections containing a 30% glucose solution (2 g/kg
body weight) (Fresenius Kabi, Uppsala, Sweden). For the IPInsTT,
random-fed mice were injected i.p. with human recombinant insu-
lin (Humalog, Eli Lilly, Indianapolis, IA) equivalent to 1 unit/kg
body weight blood was drawn from the tail vein and glycaemia
was measured using a glucometer (OneTouch Ultra 2, LifeScan
Inc., Milpitas, CA), immediately before (time 0), 5, 15, 30 and
60 min after the injection. Area under the curve (AUC) for the IPI-
nsTT was calculated between 0 and 60 min and the rate for glucose
disappearance (Kitt) was calculated from the slope of the regressionline obtained between 0 and 30 min. The study was performed
according to the guidelines of Karolinska Institutet and approved
by the local animal ethics committee. Additional details on the diet
treatment are provided as Supplementary material.
2.2. Insulin determination
Serum levels of insulin were determined using mouse insulin
ELISA according to the manufacturer’s instructions (Mercodia,
Uppsala, Sweden).
2.3. Statistical analysis
Data are presented as mean values ± standard error of the mean
(mean ± S.E.M.). Student’s t-test was used when comparing the dif-
ference between two groups. For multiple comparisons, differences
were determined by one- or two-way ANOVA followed by
Bonferroni’s post hoc test (GraphPad Prism version 5). A value of
P < 0.05 was considered statistically signiﬁcant.
3. Results
Despite similar feeding behavior, Ppp5c/ mice are less prone
to diet-induced weight gain when compared with their Ppp5c+/+ lit-
termates Ppp5c/ and littermate Ppp5c+/+ mice were divided into
four cohorts. Each cohort was then placed on either a control or
a high-fat diet (HFD) for 10 weeks. Weight gain and food/water
consumption were measured weekly. Comparison of food intake
between cohorts revealed that both Ppp5c+/+ and Ppp5c/ mice
on the HFD had a higher caloric intake than mice on the control
diet. However, no difference in energy intake between the
Ppp5c+/+or Ppp5c/ mice on either diet was observed (Fig. 1a).
Water consumption was also similar among cohorts (Fig. 1b). As
known for the C57Bl/6J mouse strain [25], comparison of Ppp5c+/+
mice on HFD or control diet revealed that mice on the HFD gained
more weight than the mice fed the control diet. In contrast, the
weight gained by the Ppp5c/ cohort on the HFD was not statisti-
cally different from the Ppp5c/ or the Ppp5c+/+ cohorts fed the
control diet (Fig. 2a). Comparison of cohorts on the HFD revealed
that, starting at week four, there was a signiﬁcant difference in
body weight between Ppp5c/ and Ppp5c+/+ animals. Interestingly,
even after ten weeks the Ppp5c/mice on the HFD were similar in
weight to their wild-type littermates receiving the control diet.
Analysis of tissue mass after sacriﬁce revealed that the weight
of perirenal, epididymal and subcutaneous fat deposits all in-
creased in the Ppp5c+/+ mice after HFD feeding as compared to
the Ppp5c+/+ cohort on the control diet. This increase in fat deposits
was not observed in the Ppp5c/ mice (Fig. 2b). Notably, the per-
irenal, epididymal and subcutaneous fat tissues were signiﬁcantly
smaller when the Ppp5c/mice were compared with their Ppp5c+/
+ littermates. In contrast, a decrease in the weights of other tissues
(e.g., spleen, heart, kidney, muscle, pancreas, brain) was not ob-
served in the Ppp5c/ mice (data not shown).
3.1. Fasting serum insulin levels in Ppp5c/ mice are not elevated in
response to the HFD
Fasting serum insulin and blood glucose (FBG) levels were mea-
sured to detect diet-induced differences in insulin levels or
glycemia between the cohorts (Fig. 3). Similar to our previous
report [17], at the start of the trial, fasting insulin levels of the 8-
week-old mice were similar in the Ppp5c/ and Ppp5c+/+ animals.
After nine weeks on the diets, a statistically signiﬁcant increase
in fasting insulin levels was observed in the Ppp5c+/+ cohort on
HFD, as compared to all other cohorts. In contrast, Ppp5c/ mice
Fig. 1. Comparison of food and water intake between Ppp5c/ and Ppp5c+/+ mice on control and high-fat diets. During the study, food consumption (a) and water
consumption (b) were measured weekly for all four groups. Ppp5c+/+ mice on control diet (CD) (white bars), Ppp5c+/+ mice on high-fat diet (HFD) (black bars), Ppp5c/mice on
CD (light grey bars) and Ppp5c/ mice fed HFD (dark gray bars). Data represent the cumulative energy and water intake expressed as mean ± S.E.M., n = 7–13. ⁄denotes a
signiﬁcant difference (P < 0.05) between CD and HFD.
Fig. 2. Comparison of body weight and tissue weight between Ppp5c/ and Ppp5c+/+ mice on both diets. Body weight (in grams) was measured weekly for all four groups (a).
Ppp5c+/+ mice on control diet (CD) (white squares and bars), Ppp5c+/+ mice on high-fat diet (HFD) (black squares and bars), Ppp5c/mice on CD (light grey triangles and bars)
and Ppp5c/ mice fed HFD (dark grey inverted triangles and bars). After sacriﬁce, fat deposits (as indicated) (b) were weighed. Data represent mean ± S.E.M., n = 7–13.
⁄denotes a signiﬁcant difference (P < 0.05) between CD and HFD; denotes a signiﬁcant difference (P < 0.05) between Ppp5c+/+and Ppp5c/ mice.
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wild-type and PP5-deﬁcient mice on the control diet (Fig. 3a and
b). Comparison of FBG levels among the four cohorts revealed a
statically signiﬁcant difference between Ppp5c+/+ mice and the
Ppp5c/mice fed the control diet, with the Ppp5c/ cohort havinglower FBG levels after 9 weeks. Comparison of Ppp5c+/+ cohorts on
control and HFD revealed no difference in FBG during the course of
the study. Comparison of the Ppp5c/ cohorts on control and HFD
revealed no difference in FBG after 5 weeks, and higher FBG levels
in Ppp5c/ cohort after nine weeks on the HFD (Fig. 3c and d).
Fig. 3. Ppp5c/ mice have lower serum insulin levels, lower fasting glycemia, and augmented insulin sensitivity compared with Ppp5c+/+ mice. Ppp5c+/+ mice (striped) and
Ppp5c/mice (squared) at study start (week one) and the treatment groups consisting of Ppp5c+/+ mice on control diet (CD) (white squares and bars), Ppp5c+/+ mice on high-
fat diet (HFD) (black squares and bars), Ppp5c/mice on CD (light grey triangles and bars) and Ppp5c/mice fed HFD (dark grey triangles and bars), were fasted for 4 h before
blood samples were collected, at week one (a) (n = 15–18), week ﬁve and week nine (b) (n = 7–9) and insulin levels in the serum were measured by ELISA. At the same time
points, blood glucose was measured with a glucometer at week one (c) (n = 19–23), week ﬁve and week nine (d) (n = 7–13). Mice from both strains and on both diets were
subjected to either an insulin tolerance test (IPInsTT; n = 5–6) (e) from which the AUC (area under the curve) (f) and the rate constant for insulin tolerance test (Kitt) (g) were
calculated, or a glucose tolerance test (h–j). Bars and symbols represent mean ± S.E.M. ⁄denotes a signiﬁcant difference (P < 0.05) between CD and HFD; denotes a signiﬁcant
difference (P < 0.05) between Ppp5c+/+and Ppp5c/ mice.
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Ppp5c/ mice on HFD were similar to FBG levels in the Ppp5c+/+
mice on the control diet (Fig. 3d). Thus, the difference between
Ppp5c/ cohorts on control and HFD may in part reﬂect the lower
FBG levels observed in the Ppp5c/ cohort on the control diet.
3.2. Ppp5c/ mice have improved insulin sensitivity compared with
Ppp5c+/+ mice after HFD
In order to investigate insulin sensitivity, Ppp5c+/+ and Ppp5c/
mice on both diets were subjected to an IPInsTT (Fig. 3e). Consis-
tent with the above observations, showing elevated serum insulin
levels in the Ppp5c+/+ mice on the HFD, HFD feeding for nine weeks
in Ppp5c+/+ mice reduced insulin sensitivity as evident by both an
increased calculated AUC (Fig. 3f) and a reduced rate of glucose
disappearance (Fig. 3g) during the IPInsTT. In contrast, the insulin
sensitivity in the HFD Ppp5c/ cohort was comparable to that of
wild-type mice on the control diet (Fig. 3e–g) indicating resistance
to diet-induced insulin resistance in Ppp5c/mice. However, again
it should be noted that although the rate of glucose clearance dur-
ing an IPGTT in the Ppp5c/ cohorts after 9 weeks on the HFD was
similar to the rate of glucose clearance in the Ppp5c+/+ cohort on the
control diet (Fig. 3h), comparison of glycemia during an IPGTT
between Ppp5c/ cohorts on control or HFD revealed a signiﬁcant
increase in blood glucose levels in the Ppp5c/ mice on HFD
(Fig. 3i). It should also be noted, as we reported previously [17]
blood glucose levels during an IPGTT in the Ppp5c/ mice on the
control diet were also markedly lower when compared to the lev-
els in the wild-type mice on the control diet (Fig. 3j).
4. Discussion
The high-fat diet-fed C57Bl/6J mouse model was originally
introduced 25 years ago by Surwit et al. [25] and has become a
well-established model for studying mechanisms of impaired glu-
cose tolerance and T2DM. In this model, high-fat diet-feeding has
been shown to be accompanied by insulin resistance, glucose intol-
erance and by insufﬁcient islet compensation to the insulin resis-
tance [26]. Accordingly, this model has been widely used in
studies of the pathophysiology associated with impaired glucose
tolerance and the development of T2DM [27–29]. Having back-
crossed the PP5-deﬁcient mice against the C57Bl/6J background
[23], here we explored the consequences associated with the loss
of PP5 in the high-fat diet-fed model. The effect of PP5 deletion
was striking. Unlike the wild-type mice, which on average gained
14 gram in body mass after 9 weeks, the weight gained by the
PP5-deﬁcient mice by HFD feeding (7 gram) was similar to the
weight gain of both wild-type and PP5-deﬁcient mice on the con-
trol diet. More precisely, the increase in white adipose tissue
(WAT) deposits weight that occurred during HFD feeding in
Ppp5c+/+ mice was not observed in the Ppp5c/ mice. Although
we have not made a complete investigation of the body composi-
tion, and thus cannot rule out differences in lean mass, the striking
differences in fat deposit weight explain a large part of the ob-
served differences in body weight between Ppp5c/ and Ppp5c+/+
mice placed on a HFD. The loss of PP5 did not appear to have an
effect on satiety or hunger responses, because no differences in
cumulative energy and water intake were observed between the
cohorts of Ppp5c/ and Ppp5c+/+ mice. In fact, considering that
after 4 weeks from the start of the study the Ppp5c/ mice placed
on the HFD were smaller than the Ppp5c+/+ mice on the HFD, the
body weight-normalized energy intake from 4 weeks to the end
of the study was greater in Ppp5c/ mice than in Ppp5c+/+ mice.
At present it is not clear where the energy is going. We also
observed no evidence that the Ppp5c/ mice were more activephysically or had reduced ability to digest or absorb the fat (e.g.,
no steatorrhea). Still, the limited fat production observed here in
the Ppp5c/ mice is consistent with a study conducted with
adipose-differentiated mouse embryonic ﬁbroblast, in which
embryonic ﬁbroblasts without PP5 showed impaired lipid accumu-
lation and low levels of fatty acid synthesis in response to adipo-
genic stimuli [24]. However, additional metabolic studies will be
needed to determine the fate of the carbon contained in the dietary
fat.
Visceral obesity is closely connected to reduced insulin sensitiv-
ity [2] and is a strong risk factor for the development of T2DM [3].
Our previous studies conducted with mice on a normal diet re-
vealed that Ppp5c/ mice had lower fasting glycemia and elimi-
nated glucose faster during a glucose tolerance test, but they
retained normal insulin sensitivity and normal fasting insulin lev-
els [17]. Here we show that the avoidance of diet-induced obesity
in the Ppp5c/ mice resulted in maintained insulin sensitivity in
these animals. Mice lacking PP5, when subjected to a HFD, did
not develop hyperinsulinemia and displayed enhanced insulin sen-
sitivity compared to wild-type mice. Since the mice did not accu-
mulate fat, it is not clear if the improved insulin sensitivity in
HFD-fed Ppp5c/ cohort was simply derived from the resistance
to weight gain, or to other actions of PP5 in glucose or lipid metab-
olism, as suggested from studies with PP5-deﬁcient cells in culture
[24]. One must also consider that these mice have no PP5 during
embryonic development, and our data do not rule out the possibil-
ity that PP5 affects adipocyte differentiation. Thus, the observed
beneﬁts of PP5 deﬁciency could have originated during embryonic
life. In conclusion, while our data suggests that PP5 may be a po-
tential novel therapeutic target to combat diet-induced obesity
and insulin resistance, future studies will be needed to determine
if a pharmacological manipulation of PP5 in adult life also prevents
weight gain. These studies will require the development of strains
of mice in which PP5 can be deleted in adults, or the development
of speciﬁc small molecule inhibitors of PP5.
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